Company Summary

Cellaria will create and market cell lines for ovarian, breast, colon, lung and prostate cancer for pharma companies to use for cancer research. Cell line priorities will be set by revenue projects for pharma. Novel cell lines will also be used to create DNA/RNA control products for lab quality control, and offer service projects to develop custom cell-based assays for pharma R&D.

Team

Elin S Agoston

Co-Founder

Dr. Agoston has dedicated a significant amount of her post-doctoral work to researching and developing methods for the primary culture of tumor tissues, including ovarian, breast, and other cancers. Her work has led to the development of a novel cell culture media which she has continued to develop the media into a product while at Stemgent and her continued research efforts have created the foundation for Cellaria’s product portfolio.

Bryan Roberts

Co-Founder

Dr. Roberts has founded and established six biotechnology companies between 1982 to the present. Three companies were in the therapeutic area focused on the control and prevention of infectious diseases and the most recent company Stemgent is a stem cell reagent and service company. He has had career long interest/involvement in global health with focus on new approaches to infectious disease prevention and control in the developing world.

David Deems

Principal

David Deems has over 25 years in life sciences and diagnostics with a focus on development and validation of novel technologies for new or emerging markets. David has developed and successfully launched novel products into the diagnostic and drug discovery markets, for both large and small companies, including Becton Dickinson, EXACT Sciences, Predicant Biosciences and, most recently, as CEO of Xceed Molecular, a molecular diagnostics company.

Joseph S Gentile

Founder/Investor

With over 28 years of global medical device and life science industry experience, Mr. Gentile is Executive Vice President/COO of Stemgent, a life science tools company with operations in Cambridge, MA, Detroit, MI and UK. Mr. Gentile is an investor in Genometry, Inc, and Firefly Bioworks, and serves as a board advisor. In addition, he is a board advisor for New England Healthcare Institute and Virtify, Inc, and is a director for ChanTest, Inc.